US OptionsDetailed Quotes
AMPH250117C45000
- 0.45
- 0.000.00%
15min DelayTrading Dec 20 15:35 ET
0.00High0.00Low
0.00Open0.45Pre Close0 Volume1 Open Interest45.00Strike Price0.00Turnover115.31%IV29.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.1361Delta0.0307Gamma77.83Leverage Ratio-0.0694Theta0.0013Rho10.59Eff Leverage0.0135Vega
Amphastar Pharmaceuticals Stock Discussion
Sign in to post a comment
The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...
Jefferies analysts cited 10 possible policies that Tr...
31
8
43
$Amphastar Pharmaceuticals (AMPH.US)$ 📣 Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
3
The market's growth expectations seem moderated as EPS growth outpaces average annual share price increase. The recent rise in total shareholder return could suggest business improvement over time.
The impressive EPS growth and large insider ownership make Amphastar Pharmaceuticals a potentially attractive investment. The business appears to have reached a growth inflection point.
Insider ownership is moderately high, showing company's interest for all shareholders, but the lack of insider buying and significant selling over the last year, casts some doubt on the company's outlook.
Amphastar Pharmaceuticals experienced a dip, but long-term its performance is strong due to profitability transition and faster EPS growth versus share price. However, market growth expectations are moderated. Share price momentum indicates a potential investment opportunity.
$Amphastar Pharmaceuticals (AMPH.US)$ any good news?
second that!No comment yet
Shifting Gears : all the good shares on his side
Simon 5183 : The lower Trump's stock price, the greater the pressure from Financial Street, which means that Trump's chances of winning are greater.
dookiro : Will interest fed rate drop drastically if Trump were to win?
D3VIN dookiro : no
Mr Neitaniel :
View more comments...